Letrozole Tablet, Film Coated
Product Images NDC 68071-5264

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 68071-5264). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 5264 3)

Pdp (68071 5264 3)
The text seems to be a product label from Care Pharmaceuticals, Inc. The product is Letrozole 2.5mg Tablets, which is used to treat breast cancer. It includes details such as lot numbers, NDC codes, manufacturing and expiry dates, dosage information, and storage instructions. The label also includes a warning to keep it out of reach from children and contact FDA if needed.*
FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)
FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)
FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)
FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)
FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)
This appears to be a graph or chart displaying the time to progression in days for a treatment group using Letrozole tablets at dosages of 0.5mg and 2.5mg. The x-axis shows the number of days, while the y-axis indicates the treatment group and dosage. However, the formatting and content are not clear, and therefore, any additional information cannot be accurately provided.*
FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Letrozole Structural Formula (Letrozole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.